Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0YXZQL)
| ADC Name |
SGN-15
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SGN-15; BMS-182248; cBR96-Dox; cBR96-doxorubicin immunoconjugate; BMS-182248-01; BR96-doxorubicin conjugate
Click to Show/Hide
|
|||||
| Organization |
Bristol-Myers Squibb (Top20 MNC) (Originator) (No Rights);Seagen (Top20 MNC)
|
|||||
| Drug Status |
Phase 2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
CBR96
|
Antibody Info | ||||
| Antigen Name |
Lewis Y
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Acid-labile linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed metastatic/unresectable recurrent breast carcinoma with ≤2 prior chemotherapy regimens for metastatic disease or recurrence within 6 months post-adjuvant therapy, measurable disease/bone markers (2×ULN) with Lewis-y antigen expression, and no active brain metastases.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00028483 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
The study included patients with metastatic or recurrent NSCLC who failed 1-2 prior therapies or recurred within 6 months post-adjuvant chemo, requiring Lewis-y antigen expression and measurable/evaluable disease with ECOG ≤2 and ≥3-month life expectancy, excluding those with prior docetaxel, high anthracycline exposure, active infections, uncontrolled comorbidities, or CNS metastases.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051571 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed stage IIIB/IV NSCLC with ≥1 measurable lesion, no prior metastatic chemotherapy, ECOG ≤2, available tumor block for LeY antigen testing, approved FDG-PET, and adequate organ function, excluding candidates for curative combined therapy.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00086333 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed advanced/recurrent ovarian cancer with 2-3 prior therapy failures, ≥20% Lewis-y antigen expression, LVEF>50%, and platinum resistance (progression during/first 6 months post-treatment).
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051584 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Eligible patients had hormone-refractory prostate cancer with disease progression evidenced by tumor growth or rising PSA with metastatic disease, plus documented Lewis (Y) antigen expression via immunohistochemistry on tumor samples.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00031187 | Clinical Status | PHASE2 | ||
| Clinical Description | Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma | ||||
References